New drug may keep High-Risk kidney cancer at bay after surgery
NCT ID NCT06584435
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 16 times
Summary
This study tests whether the drug toripalimab can help prevent high-risk kidney cancer from returning after surgery to remove the kidney. About 100 adults will receive the drug by IV every three weeks for up to a year. Researchers will track how long participants stay cancer-free and monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Changyi Quan
Tianjin, Tianjin Municipality, 300211, China
Conditions
Explore the condition pages connected to this study.